Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 369

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

British Association of Dermatologists’ guidelines for the management of lichen sclerosus 2010

Open access
Neill, S.M., Lewis, F.M., Tatnall, F.M., Cox, N.H.·2010·British Journal of Dermatology

Abstract

One of the aims of the British Association of Dermatologists (BAD) is to provide guidelines for the management of skin diseases using all available good‐quality evidence‐based data. The BAD guidelines writing and consultation process, and its revised formats, have been described elsewhere.1 2–3 These guidelines for the management of lichen sclerosus (LS) have been prepared for dermatologists on behalf of the BAD. They present evidence‐based guidance for investigation and treatment, with identification of the strength of evidence available at the time of preparation of the guidelines. The guidelines have been revised and updated in accordance with a predetermined scope, based on that used in the 2002 guidelines. Recommendations in these guidelines supersede those in the 2002 guidelines. The overall objective of the guidelines is to provide up‐to‐date recommendations for the management of LS in adults and children. This guidance has been written by dermatologists and has been shown to a patient. The guidelines have also been seen by a urologist, gynaecologist and genitourinary physician, all of whom are involved in the management of patients with LS. These guidelines have been developed using the BAD’s recommendations3 and also with reference to the AGREE (Appraisal of Guidelines Research and Evaluation) instrument.4 Medline and EMBASE databases were searched from 2002 to 2009 and full relevant papers obtained. The draft guidelines were made available for consultation and review by the BAD membership; the final document was peer reviewed by the Clinical Standards Unit of the BAD (made up of the Therapy & Guidelines and Audit & Clinical Standards Subcommittees) prior to publication. There are few published randomized controlled trials to support the following guidelines for the management of LS; the recommendations made are those that are currently considered best practice but they will be modified at intervals in the light of new evidence. LS, although a dermatosis, occurs commonly at a genital site and consequently is not only managed by dermatologists; patients may be under the care of other specialist disciplines. There have been many long‐standing difficulties in the appraisal and grading of the evidence for the treatment of LS. Historically, the nomenclature used to describe LS has been unclear. In addition, there may be difficulty in assessing the number of patients with active disease as, although asymptomatic, there is still ongoing activity as evidenced by scarring. There are also instances where the LS may be in remission but the patient still experiences symptoms due to a secondary sensory disorder, or additional irritant eczema. These guidelines will be revised as necessary to reflect changes in practice. These guidelines have been prepared for dermatologists on behalf of the BAD and reflect the best data available at the time the report was prepared. Caution should be exercised in interpreting the data; the results of future studies may require alteration of the conclusions or recommendations in this report. It may be necessary or even desirable to depart from the guidelines in the interests of specific patients and special circumstances. Just as adherence to guidelines may not constitute defence against a claim of negligence, so deviation from them should not necessarily be deemed negligent. LS is an autoimmune, inflammatory dermatosis, characterized by a lymphocytic response that has a predilection for the genital skin in both sexes, and an association with several other autoimmune diseases. The aetiology of LS is uncertain but there is mounting evidence to suggest that autoimmune mechanisms are involved in its pathogenesis;5 6–7 there is an increased incidence of tissue‐specific antibodies8 and associations with other autoimmune diseases in patients with LS,9, 10 as well as positive associations with HLA class II antigens.11 12–13 There is still controversy regarding the implication of Borrelia infection as an aetiological agent; although several studies have shown that this association does not occur in the U.S.A., some doubt still remains in Europe.14, 15 The presence of circulating extracellular matrix protein antibodies gives further support to an immune aetiopathology in female patients.16‘Balanitis xerotica obliterans’ is now viewed as a synonymous term describing LS of the penis, and ‘kraurosis vulvae’ is now recognized as LS of the vulva. The term ‘leucoplakia’ (meaning white plaque) is not a diagnostic entity and is descriptive only, as many conditions may present with white plaques. The term ‘lichen sclerosus et atrophicus’ has been abbreviated to ‘lichen sclerosus’ as some cases are associated with a hypertrophic, rather than atrophic, epithelium. There are instances when it can be difficult to differentiate between LS and lichen planus (LP) on the basis of the clinical and histological features; these cases appear to constitute an overlap syndrome, which is often associated with sq

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2133.2010.09997.x

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

See all 369

Metadata

Authors
Neill, S. M., Lewis, F. M., Tatnall, F. M., & Cox, N. H.
Venue
British Journal of Dermatology
Published
2010-09-20
Volume
163
Issue
4
Pages
672-682
ISSN
0007-0963 (ISSN-L)
OpenAlex
W2165456905
Cited by
369
References
59
FWCI
22.98
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: British Association of Dermatologists’ guidelines for the management of lichen sclerosus 2010. https://app.cochat.ai/papers/10.1111/j.1365-2133.2010.09997.x
The paper
Neill, S. M., Lewis, F. M., Tatnall, F. M., & Cox, N. H. (2010). British Association of Dermatologists’ guidelines for the management of lichen sclerosus 2010. British Journal of Dermatology. https://doi.org/10.1111/j.1365-2133.2010.09997.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.